Transaldolase 1 contributes to pentose phosphate pathway disruption and synaptic dysfunction in Alzheimer's disease.
Overview
- Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025 China
- State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031 China
- Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong-Hong Kong Joint Laboratory for Stem Cell and Regenerative Medicine, Center for Cell Lineage Atlas, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530 China
- Department of Neurology & Institute of Neurology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200125 China
- Lab for Future Health, Shanghai Frotiers Science Center of TCM Chemical Biology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201210 China
Abstract
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and synaptic dysfunction. Increasing evidence suggests that impaired glucose utilization is a major contributor to AD pathogenesis. Neurons preferentially use glucose through the pentose phosphate pathway (PPP). In AD, the flux through the PPP is significantly reduced; however, the underlying mechanism is still elusive. This study was aimed to elucidate how PPP was affected in AD and its contribution to the AD pathogenesis.
Methods: Proteomic analyses of temporal cortex synaptosomes from AD patients and controls were conducted to identify dysregulated pathways and significantly affected proteins. Functional analysis was performed by knockdown or restoration of protein expression in primary cultured neurons, as well as in wild-type and 5 × FAD mice. Pseudotargeted metabolomics and biochemical, molecular, electrophysiological and behavioral assessments were performed to evaluate metabolic characteristics, redox status, mitochondrial function, synaptic plasticity and cognition.
Results: Proteomic analysis of synaptic compartments identified glucose metabolism as the most significantly dysregulated functional network in AD. Further, transaldolase 1 (TALDO1), a rate-limiting enzyme in the PPP, was identified as a key enzyme affected in AD. TALDO1 was markedly downregulated at the early stage of AD. Downregulation of TALDO1 reduced glucose metabolism by inhibiting the PPP, TCA cycle and oxidative phosphorylation, causing broad metabolic collapse. Further, downregulation of TALDO1 depleted the nicotinamide adenine dinucleotide phosphate and glutathione pools, weakening antioxidant defense, thus resulting in mitochondria impairment and reduced energy supply. These collectively drive synaptic dysfunction and cognitive decline. Conversely, restoring TALDO1 expression in 5 × FAD mice improved glucose uptake, mitigated oxidative stress, restored metabolic homeostasis, and rescued neuronal and cognitive functions.
Conclusion: These findings identify TALDO1 as a key regulator of the impaired PPP in AD and may represent a promising therapeutic target for restoring neuronal metabolic homeostasis and function.
Supplementary Information: The online version contains supplementary material available at 10.1186/
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- figshare:33118145, at figshare; found in DataCite
- figshare:33118148, at figshare; found in DataCite
- figshare:33118151, at figshare; found in DataCite
Data availability
Proteomic raw data are deposited in the iProX (https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 10 authors, 7 keywords, 13 MeSH terms, 2 funders, 70 references.
Cite
This paper
Hu, X., Yu, Y., Luo, H., Li, J., Zhang, X., Wang, G., Li, J., Li, J., Chen, H., & Qiu, Y. (2026). Transaldolase 1 contributes to pentose phosphate pathway disruption and synaptic dysfunction in Alzheimer's disease. Translational neurodegeneration, 15(1), 35. https://
BibTeX
@article{hu2026transaldo
author = {Hu, Xiaoyu and Yu, Ying and Luo, Haorui and Li, Jiabing and Zhang, Xiaofei and Wang, Gang and Li, Jianping and Li, Juan and Chen, Hongzhuan and Qiu, Yu},
title = {{Transaldolase 1 contributes to pentose phosphate pathway disruption and synaptic dysfunction in Alzheimer's disease}},
journal = {Translational neurodegeneration},
year = {2026},
month = jul,
volume = {15},
number = {1},
pages = {35},
publisher = {BMC},
issn = {2047-9158},
doi = {10.1186/
url = {https://
pmid = {42527927},
pmcid = {PMC13418138}
}
RIS
TY - JOUR
AU - Hu, Xiaoyu
AU - Yu, Ying
AU - Luo, Haorui
AU - Li, Jiabing
AU - Zhang, Xiaofei
AU - Wang, Gang
AU - Li, Jianping
AU - Li, Juan
AU - Chen, Hongzhuan
AU - Qiu, Yu
TI - Transaldolase 1 contributes to pentose phosphate pathway disruption and synaptic dysfunction in Alzheimer's disease
T2 - Translational neurodegeneration
J2 - Transl Neurodegener
PY - 2026
DA - 2026/
VL - 15
IS - 1
SP - 35
SN - 2047-9158
PB - BMC
DO - 10.1186/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1186/
"type": "article-journal",
"title": "Transaldolase 1 contributes to pentose phosphate pathway disruption and synaptic dysfunction in Alzheimer's disease",
"container-title": "Translational neurodegeneration",
"author": [
{
"family": "Hu",
"given": "Xiaoyu"
},
{
"family": "Yu",
"given": "Ying"
},
{
"family": "Luo",
"given": "Haorui"
},
{
"family": "Li",
"given": "Jiabing"
},
{
"family": "Zhang",
"given": "Xiaofei"
},
{
"family": "Wang",
"given": "Gang"
},
{
"family": "Li",
"given": "Jianping"
},
{
"family": "Li",
"given": "Juan"
},
{
"family": "Chen",
"given": "Hongzhuan"
},
{
"family": "Qiu",
"given": "Yu"
}
],
"container-title-short":
"volume": "15",
"issue": "1",
"page": "35",
"DOI": "10.1186/
"PMID": "42527927",
"PMCID": "PMC13418138",
"ISSN": "2047-9158",
"publisher": "BMC",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
7,
29
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1186/s13024-023-00634-3
- Axonal energy metabolism, and the effects in aging and neurodegenerative diseases.Journal: Molecular neurodegenerationIn common: cellular / molecular, 6 references
- [2] doi:10.1186/s40035-022-00329-7
- Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer's disease protects against mitochondrial dysfunction and mitigates brain pathology.Journal: Translational neurodegenerationIn common: Alzheimer's / dementia, mouse, cellular / molecular, 5 references
- [3] doi:10.1016/j.celrep.2022.111872
- Brain capillary pericytes are metabolic sentinels that control blood flow through a K&
lt;sub& gt;ATP& lt;/ sub& gt; channel-dependent energy switch. Journal: Cell reportsIn common: cellular / molecular, 4 references - [4] doi:10.1038/s41419-021-04237-y
- Hippocampal disruptions of synaptic and astrocyte metabolism are primary events of early amyloid pathology in the 5xFAD mouse model of Alzheimer's disease.Journal: Cell death & diseaseIn common: Alzheimer's / dementia, genetics / omics, mouse, 1 other category, 3 references
- [5] doi:10.1371/journal.pbio.3003619 [code]
- Five energy metabolism pathways show distinct regional distributions and lifespan trajectories in the human brain.Journal: PLoS biologyIn common: genetics / omics, cellular / molecular, 4 references
- [6] doi:10.1101/2025.05.01.651195 [code]
- Alzheimer’s disease risk gene <i>Wwox</
i> protects against amyloid pathology through metabolic reprogramming Journal: bioRxiv (preprint)In common: Alzheimer's / dementia, genetics / omics, cellular / molecular, 3 references - [7] doi:10.1038/s43587-025-01025-7
- Lysophosphatidylcholines
are associated with amyloidosis in early stages of Alzheimer's disease. Journal: Nature agingIn common: Alzheimer's / dementia, 4 references - [8] doi:10.3389/fphys.2021.825816
- Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives.Journal: Frontiers in physiologyIn common: cellular / molecular, 4 references
- [9] doi:10.1038/s41556-026-01910-2
- Characterizing the metabolomes of microglia, astrocytes and neurons in ageing and Alzheimer's brains.Journal: Nature cell biologyIn common: Alzheimer's / dementia, genetics / omics, mouse, 1 other category, 3 references
- [10] doi:10.2478/jtim-2022-0024
- Aberrant Energy Metabolism in Alzheimer's Disease.Journal: Journal of translational internal medicineIn common: Alzheimer's / dementia, 4 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
